Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
56.40
-1.59 (-2.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
34
35
Next >
2 Soaring Stocks to Buy and Hold Through 2023 and Beyond
↗
March 03, 2023
Investors are bidding up shares of these companies, and there are good reasons for doing so.
Via
The Motley Fool
10 Best Stocks to Buy in March 2023
↗
March 01, 2023
These diversified growth stocks could add rocket fuel to your long-term investment portfolio.
Via
The Motley Fool
Expert Ratings for CRISPR Therapeutics
↗
February 27, 2023
Via
Benzinga
Here's How Much You Can Make From Investing Your Tax Return Every Year
↗
February 27, 2023
Doing this can strengthen your retirement plan.
Via
The Motley Fool
Looking Into CRISPR Therapeutics's Return On Invested Capital
↗
February 22, 2023
Via
Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
↗
February 22, 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Via
The Motley Fool
Beat the Dow Jones With CRISPR Therapeutics Stock
↗
February 17, 2023
If approved, CRISPR's first product may deliver blockbuster sales.
Via
The Motley Fool
Top CRISPR Stocks
↗
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
↗
February 10, 2023
The gene-editing business has loads of potential, but is it enough to make you rich?
Via
The Motley Fool
2 Bruised Growth Stocks to Buy While They're Cheap
↗
February 21, 2023
Both are on the verge of fast growth, and they haven't had any major setbacks yet.
Via
The Motley Fool
SMID Cap Life Science Update: Are You An Investor Or Trader?
↗
February 20, 2023
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.
Via
Talk Markets
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer
↗
February 18, 2023
These two companies are on track to flourish through the end of the decade.
Via
The Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
↗
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
3 Prime Healthcare Takeover Targets
↗
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
↗
February 12, 2023
The time is right for each of these great stocks.
Via
The Motley Fool
Ready to Buy the Dip? Consider This Gene Editing Stock
↗
February 06, 2023
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.
Via
The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
↗
February 12, 2023
All of these players are cheap today considering their growth potential.
Via
The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
↗
February 10, 2023
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?
Via
The Motley Fool
2 Biotech Stocks That Could Make You Richer
↗
February 09, 2023
Patience will pay off with these two stocks.
Via
The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
↗
February 09, 2023
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
Via
The Motley Fool
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
↗
February 09, 2023
CRISPR shares are ripe for a rebound after dropping 46% last year.
Via
The Motley Fool
1 Beaten-Down Stock That Has a Lot to Prove in 2023
↗
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
3 Top Stocks to Buy If There Is a Market Pullback
↗
February 07, 2023
All three of these stocks performed well as the market fell in 2022.
Via
The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
↗
February 06, 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
Via
The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
↗
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
↗
February 03, 2023
These stocks all fell by double digits last year.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
↗
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
↗
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
↗
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
↗
February 02, 2023
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case?
Via
InvestorPlace
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
